Skip to main content

Table 4 Evaluation of high adherence among prevalent users by length of previous INF bio-originator use in three follow-up intervals

From: Adherence patterns in naïve and prevalent use of infliximab and its biosimilar

 

6 Monthsa

12 Monthsa

18 Monthsa

Among INF bio-originator prevalent users

 < 12 months prior use of INF bio-originator

0.94 [0.92–0.97] *

0.87 [0.83–0.91] *

0.77 [0.73–0.82] *

 ≥ 12 months prior use of INF bio-originator

Reference

Reference

Reference

Among INF biosimilar prevalent users

 < 12 months prior use of INF bio-originator

0.81 [0.52–1.25]

0.65 [0.35–1.21]

0.64 [0.18–2.35]

 ≥ 12 months prior use of INF bio-originator

Reference

Reference

Reference

All prevalent INF users with < 12 months prior

Use of INF bio-originator

   

 INF biosimilar

0.76 [0.53–1.10]

0.61 [0.35–1.06]

0.59 [0.18–1.97]

 INF bio-originator

Reference

Reference

Reference

All prevalent users with ≥ 12 months prior

Use of INF bio-originator

   

 INF biosimilar

0.70 [0.62–0.80] *

0.63 [0.52–0.76] *

0.56 [0.39–0.80] *

 INF bio-originator

Reference

Reference

Reference

  1. * indicates the p-value ≤ 0.05
  2. aRelative risks were adjusted for age, other biologic use, baseline inflammatory diseases, and hospitalization. Estimated with Log-binomial regression